Construction and Medical Trials of Monoclonal Immuno-Enzyme Test-System for the Detection of Encapsulated Plague Agent Strains, “EIAPESTF1-M”

Objective of the study was to develop and then conduct medical trials of the “Monoclonal immune-enzyme test-system for the detection of plague agent (“EIAPESTF1-M”).Materials and methods. Utilized were materials for carrying out sandwich EIA. MCA 1B3 to Y. pestis F1 served as diagnostic immune-reage...

Full description

Bibliographic Details
Main Authors: Z. L. Devdariani, N. A. Syrova, E. A. Mikheeva, I. V. Terekhova, N. M. Ermakov, G. V. Grigor’eva, O. A. Lobovikova, I. V. Shul’gina
Format: Article
Language:Russian
Published: Federal Government Health Institution, Russian Research Anti-Plague Institute “Microbe” 2016-09-01
Series:Проблемы особо опасных инфекций
Subjects:
Online Access:https://journal.microbe.ru/jour/article/view/333
Description
Summary:Objective of the study was to develop and then conduct medical trials of the “Monoclonal immune-enzyme test-system for the detection of plague agent (“EIAPESTF1-M”).Materials and methods. Utilized were materials for carrying out sandwich EIA. MCA 1B3 to Y. pestis F1 served as diagnostic immune-reagent. To determine sensitivity and specificity of the designed immune-enzyme test-system, investigated were samples of 24 natural and genetically modified pFra+ and pFra– Y. pestis strains and 56 strains of heterologous bacteria Enterobacteriaceae family.Results and conclusions. Based on monoclonal antibodies to Yersinia pestis capsular antigen, constructed was “Monoclonal immune-enzyme test-system for the detection of plague agent (“EIAPESTF1-M”), which is characterized by high specificity and allows for the detection of encapsulated plague agent strains in biological samples and for identification of pure cultures with sensitivity of 5·105 – 1·106 mc/ml. It is highly competitive with comparator drug – “Diagnostic fluorescent absorbed equine plague immunoglobulins”, lyophilizate for diagnostic purposes, by RusRAPI “Microbe”. It possesses such advantages as objective result recording and capability of result documentation. “EIAPESTF1-M” is registered in the RF Federal Service for Surveillance in the Sphere of Healthcare and Social Development, reference No 2013/711, dated 31.05.2013 and approved for use in the territory of the Russian Federation.
ISSN:0370-1069
2658-719X